A world-class network of partners and collaborators.
We collaborate with international pharmaceutical leaders and innovative early-stage companies as well as academic institutions and other research organizations to advance our portfolio.
CSL Behring has acquired exclusive global license rights to commercialize AMT-061 (etranacogene dezaparvovec), for the treatment of hemophilia B. Under the terms of the agreement, uniQure will complete the Phase 3 trial and scale up manufacturing for early commercial supply.
Bristol-Myers Squibb Company and uniQure have an agreement that provides Bristol-Myers Squibb with exclusive access to uniQure’s gene therapy technology platform for four targets.
4D Molecular Therapeutics
uniQure has a collaboration and license agreement with 4D Molecular Therapeutics that is focused on the identification of novel optimized AAV variants that have greatly enhanced properties for achieving higher levels of gene expression. The collaboration will evolve AAV variants with greatly improved gene delivery properties in liver and the central nervous system.
We have a license agreement with Synpromics Limited for the discovery of alternative small liver-specific promoters for sustainable and increased expression of larger therapeutic genes fitting the package capacity of AAV vectors.
We have entered into an exclusive research collaboration and license agreement with Gen‑X to identify novel synthetic promoters for use in gene therapy products. During the collaboration, Gen‑X will work with uniQure to develop promoters for CNS programs within the uniQure research pipeline.
Academic and Research Institutions
In addition, uniQure collaborates with leading academic institutions and other research organizations that are sponsoring preclinical and early-stage clinical trials of gene therapy product candidates to which the company holds specified rights.